Can PBMCs be used as a tool for the identification of immune biomarkers in lung cancer?

Lung cancer is a leading cause of cancer-related deaths worldwide, with treatment responses varying widely among patients.Dr. Carminia Maria Della Corte from the University of Texas MD Anderson Cancer Center is at the forefront of research into using peripheral blood mononuclear cells (PBMCs) to identify immune biomarkers. Her work explores the cGAS/STING pathway, DDR gene mutations, and advanced 3D tumour models, offering insight into predicting immunotherapy responses and tailoring treatments for non-small and small cell lung cancer.Read the original research: doi.org/10.3390/biomedicines12040809